Temperature affects thrombolytic efficacy using rt-PA and eptifibatide, an in vitro study

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Science

Background:

• Hypothermia is increasingly used for neuroprotection during stroke.
• Combination therapies involving rt-PA and GP IIb-IIIa inhibitors like Eptifibatide are being investigated for ischemic stroke.
• Limited data exists on temperature's impact on these thrombolytic agents.

Purpose of the Study:

• To investigate the effect of hypothermic temperatures on the lytic efficacy of rt-PA and Eptifibatide combination therapy in an in vitro human clot model.
• To test the hypothesis that decreasing temperature reduces the lytic efficacy of rt-PA and Eptifibatide.

Main Methods:

• Human whole blood clots from 31 volunteers were used.
• Clots were exposed to rt-PA + Eptifibatide, rt-PA alone, or plasma alone (control) at temperatures ranging from 30°C to 37°C for 30 minutes.
• Lytic efficacy was measured by fractional clot loss (FCL) using microscopic imaging.

Main Results:

• Temperature significantly impacted FCL in rt-PA + Eptifibatide treated clots; FCL was lower at 30°C-36°C compared to 37°C.
• rt-PA + Eptifibatide significantly increased FCL compared to controls at most temperatures, except at 30°C where no significant difference was observed.
• Lytic efficacy of the combination therapy decreased with decreasing temperature.

Conclusions:

• Hypothermia, while beneficial for neuroprotection, may diminish the therapeutic effectiveness of rt-PA and Eptifibatide combination therapy for ischemic stroke.
• Further research is needed to balance the neuroprotective effects of hypothermia with the efficacy of thrombolytic treatments.